Trimetazidine Hcl
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09069 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 30 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 2 | endolymphatic hydrops | KG + DL |
| 3 | active cochlear Meniere disease | KG + DL |
| 4 | active cochleovestibular Meniere disease | KG + DL |
| 5 | active vestibular Meniere disease | KG + DL |
| 6 | exocrine pancreatic insufficiency | KG + DL |
| 7 | vertigo, benign recurrent, 2 | KG + DL |
| 8 | 46,XY disorder of gonadal development | KG + DL |
| 9 | male infertility due to gonadal dysgenesis | KG + DL |
| 10 | metastatic melanoma | KG + DL |
| 11 | non-cutaneous melanoma | KG + DL |
| 12 | choroideremia | KG + DL |
| 13 | epithelioid cell melanoma | KG + DL |
| 14 | eyelid melanoma | KG + DL |
| 15 | choroidal dystrophy, central areolar | KG + DL |
| 16 | gonadal dysgenesis | KG + DL |
| 17 | scrotum melanoma | KG + DL |
| 18 | balloon cell malignant melanoma | KG + DL |
| 19 | CDK4 linked melanoma | KG + DL |
| 20 | acral lentiginous melanoma (disease) | KG + DL |
| 21 | superficial spreading melanoma | KG + DL |
| 22 | malignant melanoma of the mucosa | KG + DL |
| 23 | amelanotic skin melanoma | KG + DL |
| 24 | lentigo maligna melanoma | KG + DL |
| 25 | nodular malignant melanoma | KG + DL |
| 26 | intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency | KG + DL |
| 27 | peripheral vertigo | KG + DL |
| 28 | Meniere disease | KG + DL |
| 29 | age-related hearing impairment | KG + DL |
| 30 | otosclerosis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.